Company: CDT
Filing Date: 2025-02-11
Form Type: CORRESP
Source: 0001493152-25-005917
Chunk: 0

Company: CDT Equity Inc.
Filing Date: 2025-02-11
Form: CORRESP
Chunk 0
---
<div align='center'>Conduit Pharmaceuticals Inc.

4581 Tamiami Trail North, Suite 200

Naples, Florida 34103

(648) 491-9132

February 11, 2025</div>

VIA EDGAR SUBMISSION

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

| Re: | Conduit                                                                    
 Pharmaceuticals Inc. (the “Company”)                                       |
|     | Registration                                                               
 Statement on Form S-3 (File No. 333-284714) (the “Registration Statement”) |

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended ,the Company hereby requests that the U.S. Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement to become effective on February 12, 2025, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable, unless the Company notifies you otherwise prior to such time.

If you have any questions regarding this request, please contact our outside counsel, Todd Mason of Thompson Hine LLP, by telephone at (212) 908-3946 or via email at Todd.Mason@ThompsonHine.com. Please also call Todd Mason as soon as the Company’s Registration Statement has been declared effective. Thank you for your attention to this matter.

| Sincerely,           |                   |
| CONDUIT              
 PHARMACEUTICALS Inc. |                   |
| By:                  | /s/               
 David Tapolczay   |
| Name:                | David             
 Tapolczay         |
| Title:               | Chief             
 Executive Officer |

| cc: | Todd                     
 Mason, Thompson Hine LLP |